Novel multimodality imaging for the evaluation of obstructed urinary system in kidney stone disease patients.

| Recruitment status | Prospectively registered | | |
|--|--|--|--|
| No longer recruiting | [_] Protocol | | |
| Overall study status | [] Statistical analysis plan | | |
| Completed | [X] Results | | |
| Condition category Urological and Genital Diseases | Individual participant data | | |
| | Recruitment status No longer recruiting Overall study status Completed Condition category Urological and Genital Diseases | | |

Plain English summary of protocol

Background and study aims

Abdominal pain is a common reason people end up in the emergency room, and about 5% of these cases are due to kidney stone disease (KSD). This condition affects 13% of men and 7% of women, and if not treated properly, it can come back in 50% of cases within 5 years. In the United States, dealing with KSD costs around \$5 billion each year, covering hospital stays, procedures to remove stones, and lost work hours.

Experts from the American Urological Association (AUA) and the American College of Radiology (ACR) recommend using CT scans as the first imaging test for these patients. However, while CT scans can identify the presence of kidney stones and certain signs of blockage, they don't directly show whether there's an obstruction, how well the kidneys are working, or the flow dynamics of urine. Instead, they rely on secondary signs like "fat stranding" or a dilated collection system to determine if there's a blockage, but these signs aren't very reliable, with only a 56% accuracy.

It's crucial to rule out obstruction quickly because kidney function can recover if treated promptly. If left untreated for weeks, though, obstruction can cause irreversible damage and potentially lead to chronic kidney failure. Outflow obstruction from the kidney can also cause other issues like chronic tubulointerstitial disease, bladder residual urine, chronic or recurring urinary tract infections, incontinence, and problems from long-term catheter use.

There's a common belief that stones smaller than 5 mm will pass through the urinary system on their own, but recent studies dispute this idea. Stones as small as 4 mm may not naturally be expelled. MAG3 scintigraphy, a test using 99mTc-MAG3, has been found to detect some degree of obstruction in up to 50% of cases with silent ureteral stones (stones without symptoms). This method, done with conventional gamma camera/scintigraphy, has a high positive predictive value (PPV) of 90.6% for diagnosing obstructive kidney disease.

Advanced equipment, like Digital SPECT/CT, can perform both a CT scan and a 99mTc-MAG3 digital scintigraphy simultaneously. Our research group, with previous experience in diagnostic

imaging and kidney stones, aims to build on this by using state-of-the-art equipment to further our understanding of these conditions.

Who can participate? Adult patients with a confirmed kidney stone disease at CT.

What does the study involve? We will perform a SPECT/CT study in a novel CZT camera as part of routine care.

What are the possible benefits and risks of participation? The expected benefit is the detection and better characterization of obstruction secondary to kidney stone disease. The risk is would be increased pain during the study due to the use of a diuretical agent.

Where is the study run from? Clinical Physiology Department, Nuclear Medicine Unit, Linköping University Hospital (Sweden)

When is the study starting and how long is it expected to run for? February 2019 to March 2024

Who is funding the study? Linköping University Hospital, Clinical Physiology Department (Sweden).

Who is the main contact? Miguel Ochoa Figueroa, MD, PhD, miguel.ochoa.figueroa@regionostergotland.se

Contact information

Type(s) Public, Scientific, Principal Investigator

Contact name Dr Miguel Ochoa Figueroa

ORCID ID http://orcid.org/0000-0001-9444-8225

Contact details Fysiologiska Kliniken Universitetssjukhuset Linköping Sweden 58963 +46 101039090 miguel.ochoa.figueroa@regionostergotland.se

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers Nil known

Study information

Scientific Title

Diagnostic performance of MAG-3 SPECT/CT in the detection of obstruction of the urinary system caused by kidney stone disease, comparison with stand alone CT.

Study objectives

The degree of functional and hydrodynamical stress exerted on the urinary tract in acute obstruction is in direct proportion to the degree of alterations in function, vascular distribution and cellular perinephric changes in the kidney and determines irreversible changes in its morphology and function. SPECT-CT 99mTc-MAG3 can lead to better diagnosis of kidney stone disease and obstruction of the urinary tract, which will lead to better patient care and optimization of resources.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 13/05/2019, Etiksprövningsmyndigheten (Box 2110, Uppsala, 75002, Sweden; +46104750800; registrator@etikprovning.se), ref: 2019-01608

Study design Observational case series

Primary study design Observational

Secondary study design Case series

Study setting(s) Hospital

Study type(s) Diagnostic

Participant information sheet See study outputs table

Health condition(s) or problem(s) studied Kidney stone disease

Interventions

This is a study that included patients with kidney stone disease, confirmed by CT, who later accepted to be included in the study which consided in performing a SPECT/CT. The scintigraphy study is performed using a new digital cadmium zinc telluride (CZT) camera which has the ability to acquire 3D images SPECT/CT. Both studies are routinely performed in our centre and are wellestablished studies in these patients worldwide, although in different time points. The approach is to do both at the same time, in order to save time and resources, using a one-stop shop approach.

Intervention Type

Device

Pharmaceutical study type(s)

Not Applicable

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

MAG-3 Nephromag, furosemid

Primary outcome measure

Accuracy, sensitivity, specificity, positive predictive value and negative predictive value of the test using a digital CZT (cadmium-inctelluride) multimodality equipment SPECT-CT (single-photon emission computed tomographycomputed tomography) at one timepoint in patients with kidney stone disease to evaluate obstruction of the urinary system.

Secondary outcome measures

Accuracy, sensitivity, specificity, positive predictive value and negative predictive value of the test for the evaluation of obstruction of the urinary system using only data from CT, using data only from SPECT and its combination.

Overall study start date

01/02/2019

Completion date 15/03/2024

Eligibility

Key inclusion criteria

Adult patients who come to the emergency department due to renal colic and have kidney stone disease confirmed at the emergency CT.

Participant type(s) Patient

Age group Adult **Lower age limit** 18 Years

Upper age limit 100 Years

Sex Both

Target number of participants 40

Total final enrolment 20

Key exclusion criteria Under age (<18 years)

Date of first enrolment 23/02/2022

Date of final enrolment 15/01/2024

Locations

Countries of recruitment Sweden

Study participating centre Linköping University Hospital Universitetssjukhuset Linköping Sweden 58185

Sponsor information

Organisation Fysiologiska Kliniken i Linköping

Sponsor details

C/o: Meriam Åström Aneq. MD, PhD Chief of the Department of Clinical Physiology University Hospital Linköping Sweden 581 85 +46 101039090 Meriam.Astrom.Aneq@regionostergotland.se

Sponsor type Hospital/treatment centre

Website https://www.regionostergotland.se/

Funder(s)

Funder type Hospital/treatment centre

Funder Name Fysiologiska Kliniken, Linköping University Hospital

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

01/06/2024

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon reasonable request. Miguel Ochoa Figueroa, MD, PhD. miguel.ochoa. figueroa@regionostergotland.se. Consent from participants was required and obtained. The type of data that can be shared will depend on what is permitted by Swedish law.

IPD sharing plan summary

Available on request

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-------------------------------|---------|--------------|------------|----------------|-----------------|
| Participant information sheet | | | 24/11/2023 | No | Yes |
| <u>Results article</u> | | 02/09/2024 | 02/09/2024 | Yes | No |